Literature DB >> 18557789

Dynamic expression of protective CEACAM1 on melanoma cells during specific immune attack.

Gal Markel1, Rachel Seidman, Yifat Cohen, Michal J Besser, Tali Cohen Sinai, Avraham J Treves, Arie Orenstein, Raanan Berger, Jacob Schachter.   

Abstract

An efficient immune response against tumours depends on a well-orchestrated function of integrated components, but is finally exerted by effector tumour-infiltrating lymphocytes (TIL). We have previously reported that homophilic CEACAM1 interactions inhibit the specific killing and interferon-gamma (IFN-gamma) release activities of natural killer cells and TIL. In this study a model for the investigation of melanoma cells surviving long coincubation with antigen-specific TIL is reported. It is demonstrated that the surviving melanoma cells increase their surface CEACAM1 expression, which in turn confers enhanced resistance against fresh TIL. Furthermore, it is shown that this is an active process, driven by specific immune recognition and is at least partially mediated by lymphocyte-derived IFN-gamma. Similar results were observed with antigen-restricted TIL, either autologous or allogeneic, as well as with natural killer cells. The enhanced CEACAM1 expression depends, however, on the presence of IFN-gamma and sharply drops within 48 hr. This may be a mechanism that allows tumour cells to transiently develop a more resistant phenotype upon recognition by specific lymphocytes. Therefore, this work substantiates the melanoma-promoting role of CEACAM1 and marks it as an attractive target for novel immunotherapeutic interventions.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18557789      PMCID: PMC2632681          DOI: 10.1111/j.1365-2567.2008.02888.x

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  50 in total

1.  Redefined nomenclature for members of the carcinoembryonic antigen family.

Authors:  N Beauchemin; P Draber; G Dveksler; P Gold; S Gray-Owen; F Grunert; S Hammarström; K V Holmes; A Karlsson; M Kuroki; S H Lin; L Lucka; S M Najjar; M Neumaier; B Obrink; J E Shively; K M Skubitz; C P Stanners; P Thomas; J A Thompson; M Virji; S von Kleist; C Wagener; S Watt; W Zimmermann
Journal:  Exp Cell Res       Date:  1999-11-01       Impact factor: 3.905

2.  Homophilic adhesion of human CEACAM1 involves N-terminal domain interactions: structural analysis of the binding site.

Authors:  S M Watt; A M Teixeira; G Q Zhou; R Doyonnas; Y Zhang; F Grunert; R S Blumberg; M Kuroki; K M Skubitz; P A Bates
Journal:  Blood       Date:  2001-09-01       Impact factor: 22.113

3.  SHP1 phosphatase-dependent T cell inhibition by CEACAM1 adhesion molecule isoforms.

Authors:  Takashi Nagaishi; Lily Pao; Sue-Hwa Lin; Hideki Iijima; Arthur Kaser; Shuo-Wang Qiao; Zhangguo Chen; Jonathan Glickman; Sonia M Najjar; Atsushi Nakajima; Benjamin G Neel; Richard S Blumberg
Journal:  Immunity       Date:  2006-11-02       Impact factor: 31.745

Review 4.  The roles of IFN gamma in protection against tumor development and cancer immunoediting.

Authors:  Hiroaki Ikeda; Lloyd J Old; Robert D Schreiber
Journal:  Cytokine Growth Factor Rev       Date:  2002-04       Impact factor: 7.638

5.  CD66a interactions between human melanoma and NK cells: a novel class I MHC-independent inhibitory mechanism of cytotoxicity.

Authors:  Gal Markel; Niva Lieberman; Gil Katz; Tal I Arnon; Michal Lotem; Olga Drize; Richard S Blumberg; Erez Bar-Haim; Reuven Mader; Lea Eisenbach; Ofer Mandelboim
Journal:  J Immunol       Date:  2002-03-15       Impact factor: 5.422

Review 6.  NK cells and NKT cells in innate defense against viral infections.

Authors:  C A Biron; L Brossay
Journal:  Curr Opin Immunol       Date:  2001-08       Impact factor: 7.486

7.  CD4+ T cell--mediated tumor rejection involves inhibition of angiogenesis that is dependent on IFN gamma receptor expression by nonhematopoietic cells.

Authors:  Z Qin; T Blankenstein
Journal:  Immunity       Date:  2000-06       Impact factor: 31.745

Review 8.  KIR: diverse, rapidly evolving receptors of innate and adaptive immunity.

Authors:  Carlos Vilches; Peter Parham
Journal:  Annu Rev Immunol       Date:  2001-10-04       Impact factor: 28.527

9.  CEACAM1 regulates insulin clearance in liver.

Authors:  Matthew N Poy; Yan Yang; Khadijeh Rezaei; Mats A Fernström; Abraham D Lee; Yoshiaki Kido; Sandra K Erickson; Sonia M Najjar
Journal:  Nat Genet       Date:  2002-02-19       Impact factor: 38.330

10.  Neisserial binding to CEACAM1 arrests the activation and proliferation of CD4+ T lymphocytes.

Authors:  Ian C Boulton; Scott D Gray-Owen
Journal:  Nat Immunol       Date:  2002-02-19       Impact factor: 25.606

View more
  24 in total

1.  Tumor angiogenesis mediated by myeloid cells is negatively regulated by CEACAM1.

Authors:  Rongze Lu; Maciej Kujawski; Hao Pan; John E Shively
Journal:  Cancer Res       Date:  2012-03-09       Impact factor: 12.701

Review 2.  Cell-state dynamics and therapeutic resistance in melanoma from the perspective of MITF and IFNγ pathways.

Authors:  Xue Bai; David E Fisher; Keith T Flaherty
Journal:  Nat Rev Clin Oncol       Date:  2019-09       Impact factor: 66.675

Review 3.  Adaptive Immune Resistance: How Cancer Protects from Immune Attack.

Authors:  Antoni Ribas
Journal:  Cancer Discov       Date:  2015-08-13       Impact factor: 39.397

4.  The possible roles of OPN-regulated CEACAM1 expression in promoting the survival of activated T cells and the apoptosis of oral keratinocytes in oral lichen planus patients.

Authors:  Gui-Xiang Liu; Qi Xie; Cheng-Jun Zhou; Xiao-Ying Zhang; Bo-Long Ma; Cheng-Qin Wang; Feng-Cai Wei; Xun Qu; Shan-Zhen Sun
Journal:  J Clin Immunol       Date:  2011-06-14       Impact factor: 8.317

5.  ICAM-1-mediated adhesion is a prerequisite for exosome-induced T cell suppression.

Authors:  Wei Zhang; Wenqun Zhong; Beike Wang; Jiegang Yang; Jingbo Yang; Ziyan Yu; Zhiyuan Qin; Alex Shi; Wei Xu; Cathy Zheng; Lynn M Schuchter; Giorgos C Karakousis; Tara C Mitchell; Ravi Amaravadi; Meenhard Herlyn; Haidong Dong; Phyllis A Gimotty; George Daaboul; Xiaowei Xu; Wei Guo
Journal:  Dev Cell       Date:  2022-01-31       Impact factor: 12.270

Review 6.  The role of CEA-related cell adhesion molecule-1 (CEACAM1) in vascular homeostasis.

Authors:  Uwe Rueckschloss; Stefanie Kuerten; Süleyman Ergün
Journal:  Histochem Cell Biol       Date:  2016-09-30       Impact factor: 4.304

Review 7.  Interferons and the Immunogenic Effects of Cancer Therapy.

Authors:  Andy J Minn
Journal:  Trends Immunol       Date:  2015-11       Impact factor: 16.687

8.  Acquired resistance to immunotherapy and future challenges.

Authors:  Nicholas P Restifo; Mark J Smyth; Alexandra Snyder
Journal:  Nat Rev Cancer       Date:  2016-02       Impact factor: 60.716

9.  Natural killer lysis receptor (NKLR)/NKLR-ligand matching as a novel approach for enhancing anti-tumor activity of allogeneic NK cells.

Authors:  Gal Markel; Rachel Seidman; Michal J Besser; Naama Zabari; Rona Ortenberg; Ronnie Shapira; Avraham J Treves; Ron Loewenthal; Arie Orenstein; Arnon Nagler; Jacob Schachter
Journal:  PLoS One       Date:  2009-05-19       Impact factor: 3.240

10.  Development of allogeneic NK cell adoptive transfer therapy in metastatic melanoma patients: in vitro preclinical optimization studies.

Authors:  Michal J Besser; Tsipi Shoham; Orit Harari-Steinberg; Naama Zabari; Rona Ortenberg; Arkadi Yakirevitch; Arnon Nagler; Ron Loewenthal; Jacob Schachter; Gal Markel
Journal:  PLoS One       Date:  2013-03-04       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.